Neuropeptide Y receptor

Last updated
neuropeptide Y receptor Y1
Identifiers
SymbolNPY1R
Alt. symbolsNPYR
NCBI gene 4886
HGNC 7956
OMIM 162641
RefSeq NM_000909
UniProt P25929
Other data
Locus Chr. 4 q31.3-q32
Search for
Structures Swiss-model
Domains InterPro
neuropeptide Y receptor Y2
Identifiers
SymbolNPY2R
NCBI gene 4887
HGNC 7957
OMIM 162642
RefSeq NM_000910
UniProt P49146
Other data
Locus Chr. 4 q31
Search for
Structures Swiss-model
Domains InterPro
pancreatic polypeptide receptor 1
Identifiers
SymbolPPYR1
Alt. symbolsNPY4R, Y4, PP1
NCBI gene 5540
HGNC 9329
OMIM 601790
RefSeq NM_005972
UniProt P50391
Other data
Locus Chr. 10 q11.2
Search for
Structures Swiss-model
Domains InterPro
neuropeptide Y receptor Y5
Identifiers
SymbolNPY5R
NCBI gene 4889
HGNC 7958
OMIM 602001
RefSeq NM_006174
UniProt Q15761
Other data
Locus Chr. 4 q31-q32
Search for
Structures Swiss-model
Domains InterPro

Neuropeptide Y receptors are a family of receptors belonging to class A G-protein coupled receptors and they are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide. [1] These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety. [2] [3] [4] [5] [6] [7]

Contents

Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP.

Only the crystal structure of Y1 in complex with two antagonist is available. [8]

Types

There are five known mammalian neuropeptide Y receptors designated Y1 through Y5. [9] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders. [10] [11] [12]

Antagonists

References

  1. ↑ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID   9549761.{{cite journal}}: CS1 maint: url-status (link)
  2. ↑ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides. 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID   15337373. S2CID   37034137.
  3. ↑ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids. 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID   16738800. S2CID   2017793.
  4. ↑ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry. 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID   17979774.
  5. ↑ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery. 1 (3): 315–24. doi:10.2174/157488906778773689. PMID   18221213.
  6. ↑ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry. 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID   17979780.
  7. ↑ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.). 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID   18725086.
  8. ↑ Yang Z, Han S, Keller M, Kaiser A, Bender BJ, Bosse M, Burkert K, Kögler LM, Wifling D, Bernhardt G, Plank N, Littmann T, Schmidt P, Yi C, Li B, Ye S, Zhang R, Xu B, Larhammar D, Stevens RC, Huster D, Meiler J, Zhao Q, Beck-Sickinger AG, Buschauer A, Wu B (April 2018). "1 receptor". Nature. 556 (7702): 520–524. doi:10.1038/s41586-018-0046-x. PMC   5920736 . PMID   29670288.
  9. ↑ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides. 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID   15337367. S2CID   43696257.
  10. ↑ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews. 28 (6): 664–84. doi: 10.1210/er.2007-0003 . PMID   17785427.
  11. ↑ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry. 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID   17979781.
  12. ↑ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry. 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID   17979782.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.